Rationale for PARP inhibitor combinations for advanced prostate cancer - Conversation 1
touchMDT for touchONCOLOGY
Listen to an oncology pharmacist and a medical oncologist discuss the rationale for PARP inhibitors for the treatment of advanced prostate cancer.
The multidisciplinary team
Oncology Pharmacist: Dr Lisa Holle, USA
Medical Oncologist: Dr Wassim Abida, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Pfizer. This activity is jointly provided by USF Health and touchIME.
For further information visit our website…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.